Researchers think the injectable drug could help limit the weight people regain after stopping GLP-1 medications. It is still experimental.
Recap by typeshit. Post by @medicine_today_net on Instagram.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
The obesity doctor responds to upset replies on an earlier post, holding that adiposity and cardiorespiratory fitness are correlated yet separate measures.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Loading…